Close

Form D/A FARALLON CAPITAL OFFSHOR Mar 7, 2025 09:47AM
Form D/A Farallon Capital Partner Mar 7, 2025 09:42AM
Form D/A Farallon Capital (AM) Mar 7, 2025 09:37AM
Form D/A Farallon Capital Institu Mar 7, 2025 09:32AM
Form SCHEDULE 13D/A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P. Mar 5, 2025 05:02PM
View Older Stories

Feb 18, 2025 03:37PM Form SCHEDULE 13G Aramark Filed by: Farallon Capital Partners, L.P.
Feb 18, 2025 03:37PM Form SCHEDULE 13G NEW YORK TIMES CO Filed by: Farallon Capital Partners, L.P.
Feb 14, 2025 09:01AM Form 13F-NT Farallon Capital Europe For: Dec 31
Feb 14, 2025 09:01AM Form 13F-HR FARALLON CAPITAL MANAGEM For: Dec 31
Feb 14, 2025 09:00AM Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
Feb 14, 2025 08:59AM Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
Feb 14, 2025 08:59AM Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
Feb 12, 2025 12:04AM Farallon Capital Builds Over 3% Position In Japan's Astellas- FT
Feb 11, 2025 05:14PM Form SCHEDULE 13G/A Savara Inc Filed by: Farallon Capital Partners, L.P.
Feb 11, 2025 12:11PM Form SCHEDULE 13G/A ENANTA PHARMACEUTICALS Filed by: Farallon Capital Partners, L.P.
Feb 10, 2025 02:33PM Form SCHEDULE 13G/A AleAnna, Inc. Filed by: Farallon Capital Partners, L.P.
Feb 10, 2025 12:47PM Form SCHEDULE 13G/A Forte Biosciences, Inc. Filed by: Farallon Capital Partners, L.P.
Feb 10, 2025 09:00AM Form SCHEDULE 13G/A Protagonist Therapeutics Filed by: Farallon Capital Partners, L.P.
Feb 5, 2025 07:31PM Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: Farallon Capital Partners, L.P.
Feb 5, 2025 05:24PM Form SCHEDULE 13G/A NEW YORK TIMES CO Filed by: Farallon Capital Partners, L.P.
Feb 5, 2025 04:28PM Form SCHEDULE 13G/A Elevation Oncology, Inc. Filed by: Farallon Capital Partners, L.P.
Feb 5, 2025 01:10PM Form SCHEDULE 13G/A Lantheus Holdings, Inc. Filed by: Farallon Capital Partners, L.P.
Feb 4, 2025 12:02PM Form SCHEDULE 13G/A AGIOS PHARMACEUTICALS, Filed by: Farallon Capital Partners, L.P.
Feb 3, 2025 06:31AM Tectonic Therapeutic (TECX) Announces $185M Private Placement
Nov 14, 2024 08:22PM Form SC 13G Lantheus Holdings, Inc. Filed by: Farallon Capital Partners, L.P.
Nov 14, 2024 10:21AM Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Jun 30
Nov 14, 2024 09:25AM Form 13F-NT Farallon Capital Europe For: Sep 30
Nov 14, 2024 09:24AM Form 13F-HR FARALLON CAPITAL MANAGEM For: Sep 30
Nov 8, 2024 05:15PM Form SC 13G/A Longboard Pharmaceutical Filed by: Farallon Capital Partners, L.P.
Nov 8, 2024 02:58PM Form SC 13G/A Aramark Filed by: Farallon Capital Partners, L.P.
Nov 8, 2024 02:41PM Form SC 13G/A AGIOS PHARMACEUTICALS, Filed by: Farallon Capital Partners, L.P.
Nov 8, 2024 11:56AM Form SC 13G/A Elevation Oncology, Inc. Filed by: Farallon Capital Partners, L.P.
Nov 7, 2024 09:56AM Form SC 13G/A Beam Therapeutics Inc. Filed by: Farallon Capital Partners, L.P.
Nov 6, 2024 06:34PM Form SC 13G/A Savara Inc Filed by: Farallon Capital Partners, L.P.
Nov 6, 2024 05:06PM Form SC 13G/A Swiftmerge Acquisition Filed by: Farallon Capital Partners, L.P.
Oct 16, 2024 04:36PM Form SC 13D Squarespace, Inc. Filed by: Farallon Capital Partners, L.P.
Sep 3, 2024 08:41AM Form N-PX FARALLON CAPITAL MANAGEM For: Jun 30
Aug 14, 2024 01:32PM Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
Aug 14, 2024 01:31PM Form 13F-NT Farallon Capital Europe For: Jun 30
Aug 14, 2024 01:30PM Form 13F-HR FARALLON CAPITAL MANAGEM For: Jun 30
Aug 14, 2024 06:14AM Anaptysbio (ANAB) Prices 2.75M Share Offering at $36.50/sh
Jul 8, 2024 07:34AM CASI Pharmaceuticals (CASI) announces appointment of Daniel Lang, MD as CFO and SVP
Jul 3, 2024 09:12AM Form D/A Farallon Capital F5 Inve
Jul 3, 2024 09:07AM Form D/A Farallon Capital F5 Inve
Jun 28, 2024 08:50AM Savara (SVRA) Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
May 24, 2024 03:06PM Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Mar 31
May 17, 2024 04:59PM Form SC 13G NanoString Technologies Filed by: Farallon Capital Partners, L.P.
May 15, 2024 11:18AM Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Dec 31
May 15, 2024 11:17AM Form 13F-NT Farallon Capital Europe For: Mar 31
May 15, 2024 11:16AM Form 13F-HR/A FARALLON CAPITAL MANAGEM For: Sep 30
May 15, 2024 11:14AM Form 13F-HR FARALLON CAPITAL MANAGEM For: Mar 31
May 8, 2024 04:11PM Form SC 13D/A EXELIXIS, INC. Filed by: Farallon Capital Partners, L.P.
May 2, 2024 04:01PM Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Apr 8, 2024 06:34AM Ladenburg Thalmann Upgrades Forte Biosciences Inc. (FBRX) to Buy
Mar 25, 2024 11:25AM Zambia External Bondholder Steering Committee Reaches Agreement with Zambia on Debt Restructuring
View Older Stories